Año 2025 / Volumen 117 / Número 2
Original
Immunohistochemistry staining for DNA mismatch repair proteins in endoscopic biopsies and the corresponding surgical specimen in colorectal cancer

76-83

DOI: 10.17235/reed.2024.10645/2024

Carmen Martínez Lapiedra, Alfonso García-Fadrique, María Zaida García Casado, Samuel Navarro Fos, Isidro Machado Puerto,

Resumen
Microsatellite instability is found in 15% of sporadic colorectal cancers (CRC) and 95% of hereditary CRC cases. Lynch syndrome (LS) diagnosis begins with the analysis of the surgical specimen using methods such as immunohistochemistry (IHC), which identifies changes in the nuclear expression of DNA mismatch repair (MMR) proteins. However, IHC analysis on endoscopic biopsies could provide substantial benefits. Our goal was to assess the accuracy of MMR IHC status on endoscopic biopsies in comparison to corresponding surgical specimen in a series of CRC. We retrospectively selected patients who had undergone CRC surgery between February 2011 and January 2020 and had IHC testing for MMR proteins on the surgical specimen. The study was then performed on the corresponding endoscopic biopsies and results were compared. MMR IHC staining on surgical specimens were available for 361 CRC patients and only in 154 cases for preoperative endoscopic biopsies. The concordance between MMR IHC status of the endoscopic biopsy and the surgical specimen analysis was 98.6% for the MLH1/PMS2 proteins and 100% for MSH2/MSH6. In conclusion, endoscopic biopsies of colorectal tumors serve as a suitable tissue source for the immunohistochemical analysis of DNA repair proteins. The correlation with results from the surgical specimen was notably high and discrepancies were primarily as a result of intratumoral heterogeneity within the same sample. The features of MMR protein loss in endoscopic biopsies can provide clinicians with valuable information for specific therapeutic approaches and genetic counseling.
Resumen coloquial
Microsatellite instability, a genetic feature linked to colorectal cancer (CRC), is found in 15% of sporadic cases and 95% of hereditary cases, such as those with Lynch syndrome (LS). Diagnosing LS typically involves analyzing surgical tissue for changes in DNA mismatch repair (MMR) proteins using a technique called immunohistochemistry (IHC). However, this study explored whether IHC could be effectively performed on endoscopic biopsy samples. We compared the results of MMR IHC analysis from endoscopic biopsies with those from surgical specimens in 154 patients and found a high level of agreement—98.6% for the MLH1/PMS2 proteins and 100% for MSH2/MSH6—suggesting that endoscopic biopsies are reliable for detecting MMR protein loss. These findings could help clinicians make more informed treatment decisions and provide better genetic counseling.
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Galceran J, Ameijide A, Carulla M, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017 Jul 1;19(7):799–825.
2. Atkin WS, Valori R, Kuipers EJ, et al. European guidelines for quality assurance in colorectal cancer screening and diagnosisFirst Edition Colonoscopic surveillance following adenoma removal. Endoscopy. 2012 Sep;44(SUPPL3):SE151-63.
3. Sinicrope FA, Sargent DJ. Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15; 18(6):1506–12.
4. Wheeler JMD, Bodmer WF, McC Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Vol. 47, Gut. 2000. p. 148–53.
5. Jover, MD R, Alenda, MD C, et al. Defective Mismatch-Repair Colorectal Cancer Clinicopathologic Characteristics and Usefulness of Immunohistochemical Analysis for Diagnosis. Am J Clin Pathol. 2004 Mar 1; 122(3):389–94.
6. Boland CR, Goel A. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138(6).
7. Nakayama Y, Iijima T, Inokuchi T, et al. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study. Int J Clin Oncol. 2021 Oct 1; 26(10):1881–9.
8. Evrard C, Tachon G, Randrian V, et al. Microsatellite instability: Diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer. Vol. 11, Cancers. MDPI AG; 2019.
9. Svrcek M, Lascols O, Cohen R, et al. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors. Vol. 106, Bulletin du Cancer. John Libbey Eurotext; 2019. p. 119–28.
10. Piñol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005 Apr 27;293(16):1986–94.
11. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology. Arch Pathol Lab Med. 2017 May 1;141(5):625–57.
12. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroentero. 2015 Feb 5;110(2):223–62.
13. Rubenstein JH, Enns R, Heidelbaugh J, et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015 Sep 1;149(3):777–82.
14. Balmaña J, Balaguer F, Cervantes A, et al. Familial risk-colorectal cancer: ESMO clinical practice guidelines. Ann Oncol. 2013 Oct; 24(SUPPL.6):vi73-80.
15. Snowsill T, Coelho H, Huxley N, et al. Molecular testing for Lynch syndrome in people with colorectal cancer: Systematic reviews and economic evaluation. Health Technol Assess (Rockv). 2017 Sep 1;21(51):1–238.
16. Guastadisegni C, Colafranceschi M, Ottini L, et al. Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010 Oct;46(15):2788–98.
17. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (80- ). 2017 Jul 28;357(6349):409–13. DOI: 10.1126/science.aan6733
18. Sinicrope FA, Yang ZJ. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. Vol. 7, Future Oncology. 2011. p. 467–74.
19. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Mar 10;36(8):773–9.
20. Chalabi M, Fanchi LF, Dijkstra KK et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020 Apr;26(4):566-576
21. Chalabi M, Verschoor YL, Tan PB et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024 Jun 6;390(21):1949-1958.
22. Jain A, Shafer L, Rothenmund H, et al. Suboptimal Adherence in Clinical Practice to Guidelines Recommendation to Screen for Lynch Syndrome. Dig Dis Sci. 2019 Dec 1;64(12):3489–501.
23. Noll A, J. Parekh P, Zhou M, et al. Barriers to Lynch Syndrome Testing and Preoperative Result Availability in Early-onset Colorectal Cancer: A National Physician Survey Study. Clin Transl Gastroenterol. 2018 Sep 1;9(9).
24. Kuan SF, Ren B, Brand R, et al. Neoadjuvant therapy in microsatellite-stable colorectal carcinoma induces concomitant loss of MSH6 and Ki-67 expression. Hum Pathol. 2017 May 1;63:33–9.
25. Vilkin A, Halpern M, Morgenstern S, et al. How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation? Hum Pathol. 2014 Oct 1;45(10):2029–36.
26. Bao F, Panarelli NC, Rennert H, et al. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma. Am J Surg Pathol. 2010 Dec;34(12):1798–804.
27. O’Brien O, Ryan É, Creavin B, et al. Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. J Clin Pathol. 2018 Jul;71(7):631–6.
28. Kumarasinghe AP, De Boer B, Bateman AC, et al. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: A comparison of biopsy and resection material. Pathology. 2010;42(5):414–20.
29. Shia J, Stadler Z, Weiser MR, et al. Immunohistochemical staining for dna mismatch repair proteins in intestinal tract carcinoma: How reliable are biopsy samples? Am J Surg Pathol. 2011 Mar;35(3):447–54.
30. Warrier SK, Trainer AH, Lynch AC, et al. Preoperative diagnosis of lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy. Dis Colon Rectum. 2011 Dec;54(12):1480–7.
31. Vilkin A, Leibovici-Weissman Y, Halpern M, et al. Immunohistochemistry staining for mismatch repair proteins: The endoscopic biopsy material provides useful and coherent results. Hum Pathol. 2015 Nov 1;46(11):1705–11.
32. Joost P, Veurink N, Holck S, Klarskov L, et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol. 2014 Jun 26;9(1):126.
33. McCarthy AJ, Capo-Chichi JM, Spence T, et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2019 Apr 1;5(2):115–29.
34. Hale MD, Gotoda T, Hayden JD, et al. Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: A review of the literature and recommendations for clinical practice and research. Vol. 67, Histopathology. Blackwell Publishing Ltd; 2015. p. 147–57.
Artículos relacionados

Carta

Metástasis intestinales de cáncer colorrectal

DOI: 10.17235/reed.2024.10089/2023

Imagen en Patología Digestiva

Spontaneous regression of a rectal cancer

DOI: 10.17235/reed.2023.9486/2023

Carta

Vaginal lesion as first manifestation of colorectal disease

DOI: 10.17235/reed.2022.9270/2022

Carta

No es GIST todo lo que parece

DOI: 10.17235/reed.2022.8974/2022

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Carta

Medullary colorectal carcinoma. Do we really know it?

DOI: 10.17235/reed.2020.6728/2019

Carta

The rectosigmoid junction: are limits important?

DOI: 10.17235/reed.2019.5983/2018

Editorial

Cribado del cáncer colorrectal y supervivencia

DOI: 10.17235/reed.2018.5870/2018

Revisión

Lesiones serradas y síndrome de poliposis serrada

DOI: 10.17235/reed.2017.4065/2015

Carta al Editor

Metástasis traqueobronquiales de cáncer colorrectal

DOI: 10.17235/reed.2016.4080/2015

Imagen en Patología Digestiva

Tumor de células granulares en ciego

Instrucciones para citar
Martínez Lapiedra C, García-Fadrique A, García Casado M, Navarro Fos S, Machado Puerto I. Immunohistochemistry staining for DNA mismatch repair proteins in endoscopic biopsies and the corresponding surgical specimen in colorectal cancer. 10645/2024


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1564 veces.
Este artículo ha sido descargado 66 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 10/07/2024

Aceptado: 09/10/2024

Prepublicado: 18/10/2024

Publicado: 05/02/2025

Tiempo de revisión del artículo: 70 días

Tiempo de prepublicación: 100 días

Tiempo de edición del artículo: 210 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2025 y Creative Commons. Revista Española de Enfermedades Digestivas